|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||83.80 - 83.80|
|52-week range||78.78 - 95.45|
|Beta (5Y monthly)||0.56|
|PE ratio (TTM)||19.36|
|Forward dividend & yield||3.22 (3.64%)|
|Ex-dividend date||04 Mar 2021|
|1y target est||N/A|
The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.
Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.
Unilever decides that it will not raise its offer of $68 billion for Glaxo's (GSK) Consumer Healthcare business.